TickerHumSide-by-side comparison
Becton, Dickinson and vs Biogen
As of Nov 11, 2026, P/E is 64.2x for Becton, Dickinson and vs 109.3x for Biogen; P/S is 2.6x for Becton, Dickinson and vs 3.6x for Biogen; revenue growth is 18.5% for Becton, Dickinson and vs 2.3% for Biogen; net margin is 4.2% for Becton, Dickinson and vs 3.4% for Biogen.
What stands out
- Becton, Dickinson and is growing revenue faster: 18.5% vs 2.3% for Biogen.
- Becton, Dickinson and is cheaper on earnings: 64.2x P/E vs 109.3x for Biogen.
- Biogen's shares did better over the past year: +56.4% vs +40.7% for Becton, Dickinson and.
Key metrics
| Metric | BDX | BIIB |
|---|---|---|
| Price | $212.46 | $252.57 |
| Market cap | $57.87B | $37.33B |
| P/E | 64.2x (#1) | 109.3x (#2) |
| P/S | 2.6x (#1) | 3.6x (#2) |
| Revenue growth | 18.5% (#1) | 2.3% (#2) |
| Operating margin | 10.7% (#1) | — |
| Net margin | 4.2% (#1) | 3.4% (#2) |
| Debt / equity | 0.55 (#2) | 0.39 (#1) |
| 1-year return | +40.7% (#2) | +56.4% (#1) |
| Research score | 52/100 (#2) | 53/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Becton, Dickinson and Company (BDX) — Medical Instruments & Supplies
- Biogen Inc. (BIIB) — Drug Manufacturers—General